Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced that the European Commission has granted a marketing authorization for its H5N1 adjuvanted pre-pandemic vaccine, Prepandrix, in all 27 EU member states.
Subscribe to our email newsletter
GSK’s pre-pandemic H5N1 vaccine is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen that is long-lasting and active against a broad range of H5N1 strains.
GSK is said to be the first company to obtain a European license for a pre-pandemic vaccine, thereby offering European governments the potential for protecting their population in advance or at the onset of an officially declared influenza pandemic.
A pre-pandemic vaccine is produced in advance of a pandemic. Such a vaccine is based on the currently circulating avian H5N1 influenza virus likely to cause a pandemic and has the ability to raise immune protection against potential drift H5N1 strains.